New developments in pathogenesis of systemic vasculitis

Current Opinion in Rheumatology

Volumn 10, Issue 1, 1998, Pages 3-11

  Nowack, Rainer ^a   Flores Suárez, Luis Felipe ^a   Van Der Woude, Fokko J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; LEUKOCYTE ANTIGEN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROTEINASE; TOXIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL THERAPY; APOPTOSIS; ARTERITIS; CELL INTERACTION; ENVIRONMENTAL EXPOSURE; ENZYME RELEASE; GENETIC PREDISPOSITION; HUMAN; INFECTION; INFLAMMATION; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC VASCULITIS; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; HUMANS; VASCULITIS;

EID: 0031975299     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199801000-00002     Document Type: Review

References (93)

1. Jennette JC, Falk RJ, Andrassy K: Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.
2. Weyand CM, Goronzy JJ: Giant cell arterltis as an antigen-driven disease. Rheum Dis Clin North Am 1995, 21:1027-1039.
3. Weyand CM, Goronzy JJ: Multisystem interactions in the pathogenesis • of vasculitis. Curr Opin Rheumetol 1997, 9:3-11. A complete review of determining events which might be implicated in vasculitis pathogenesis. It highlights the role of aging on T-cell repertoire and macrophage function, proposes the arterial adventitia as the site of initiation of the inflammatory process, reviews the role of different cytokines, and discusses the previous work completed in this field by the authors.
4. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG: Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 1995, 38:369-373.
5. Terai M, Miwa K, Williams T, Kabat W, Fukuyama M, Okajima Y, Igarashi H, Shulman S: The absence of evidence of staphylococcal toxin Involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995, 172:558-561.
6. Curtis N, Zheng R, Lamb JR, Levin M: Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 1995, 72:308-311.
7. Pietra BA, de Inocencio J, Giannini EM, Hirsch R: TCR V beta family repertoire and T cell activiatlon markers in Kawasaki disease. J Immunol 1994, 153:1881-1888.
8. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM, the • Dutch Cotrimoxazole Wegener Study Group: Trimetoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996, 335:16-20. A randomized, 24-months follow-up, placebo-controlled study, providing evidence that co-trimoxazole prophylaxis prevents relapses of Wegener's granulomatosis.
9. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I: The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial. Arthritis Rheum 1996, 39:2062-2065.
10. Guillevin L, Lhote F, Cohen P, Sauvage F, Jarrousse B, Lortholary O, Noel LH, Trepo C: Polyarteritis nodosa related to hepatitis B virus: a prospective study with long-term observation of 41 patients. Medicine 1995, 74:238-253.
11. Carson CW, Conn DL, Czaja AJ, Wright TL, Brecher ME: Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol 1993, 20:304-309.
12. McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP: Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up. Hepatology 1989, 9:97-101.
13. Gumber SC, Chopra SA: Hepatitis C: a multifaceted disease: review of extrahepatic manifestations. Ann Intern Med 1995, 123:615-620.
14. Pollock JL: Extrahepatic manifestations of hepatitis C virus infection. Ann Intern Med 1996, 125:345.
15. Staud R, Corman LC: Association of parvovirus B19 infection with giant cell arteritis. Clin Infect Dis 1996, 22:1123.
16. Kiraz S, Ertenli I, Benekli M, Calguneri M: Parvovirus B19 infection in Behcet's disease. Clin Exp Rheumatol 1996, 14:71-73.
17. Guillevin L, Lhote F, Ghèrardi R: The spectrum and treatment of virus-associated vasculitides. Curr Opin Rheumatol 1997, 9:31-36.
18. Sran PK, Kansipada K, Whitcup SM: Mycobacterium chelonae infection mimicking cutaneous vasculitis: case report Clin Infect Dis 1996, 23:1189-1191.
19. Zhang Y, Broser M, Cohen M, Bodkin M, Law K, Reibman J, Rom WN: Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components. J Clin Invest 1995, 95:586-592.
20. Bambery P, Joshi K, Behera D, Kaur U, Jindal SK: Wegener's granulomatosis and pulmonary tuberculosis: clinical, diagnostic, therapeutic and nosologic confusion [abstract]. Sarcoidosis Vasculitis and Diffuse Lung Diseases 1996, 13:271.
21. Flores-Suárez LF, Cabiedes J, Alcocer-Varela, Villa A: Presencla de anticuerpos anticitoplasma de neutrófilo en paclentes con tuberculosis (abstract). Revista Mexicans de Reumatologia 1996, 11(suppl 1):12.
22. Gallin M, Jacobi A, Büttner DW, Marti T, Erttmann KD: Human autoantibody to defensin: disease association with hyperreactive onchocerciasis (sowda). J Exp Med 1995, 182:41-47.
23. Qasim FJ, Mathieson PW, Thiru S, Oliveira DBG: Cyclosporin A exacerbates mercuric chloride-induced vasculitis in the brown Norway rat. Lab Invest 1995, 72:183-190.
24. Yuasa S, Hashimoto M, Yura T, Sumikura T, Takahashi N, Shoji T, Uchida K, Fujioka H, Kihara M, Matsuo H: Antineutrophil cytoplasmic antibodies (ANCA)-associated crescentic glomerulonephritis and propylthiouracil therapy. Nephron 1996, 73:701-703.
25. Bombassei GJ, Kaplan AA: The association between hydrocarbon exposure and anti-glomerular basement membrane antibody mediated disease (Goodpasture's syndrome). Am J Ind Med 1992, 21:141-153.
26. Nuyts GD, van Vlem E, de Vos A, Daelemans RA, Rorive G, Elseviers MM, Schurgers M, Segaert M, d'Haese PC, de Broe ME: Wegener granulomatosis is associated to exposure to silicon compounds: a case-control study. Nephrol Dial Transplant 1995, 10:1155-1161.
27. Knudsen BB, Jorgensen T, Munch-Jensen B: Wagener's granulomatosis in a family. Scand J Rheumatol 1988, 17:225-227.
28. Shillitoe EJ, Lehner T, Lessof MH, Harrison DFN: Immunological features of Wagener's granulomatosis. Lancet 1974, 281.
29. Numano F: Takayasu arteritis: the role of genetic factors on its pathogenesis. Vasc Med 1996, 1:227-233.
30. Hagen EC, Stegemann CA, Amaro JD, van der Woude JF, et al.: Decreased frequency of HLA-DR13DR6 in Wegener's granulomatosis. Kidney Int 1995, 48:801-805.
31. Yki-Järvinen H: MODY genes and mutations in hepatocyte nuclear factors. Lancet 1997, 349:516-517.
32. Halbwachs-Mecarelli L, Bessou G, Lesavre P, Lopez S, Witko Sarsat V: Bimodal distribution of protelnase 3 (Pr3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. FEBS Lett 1995, 374:29-33.
33. Segelmark M, Elzouki A-N, Wieslander J, Eriksson S: The PiZ gene of α1-antitrypsin as a determinant of outcome in Pr3-ANCA-positive vasculitis. Kidney Int 1995, 48:844-850.
34. Mazodier P, Elzouki A-NY, Segelmark M, Eriksson S: Systemic necrotizing vasculitides in severe α1-antitrypsin deficiency. Q J M 1996, 86:599-611.
35. Griffith ME, Lovegrove JU, Gaskin G, Whitehouse DB, Pusey CD: C-antineutrophil cytoplasmlc antibody positivity in vasculltis patients is associated with the Z-allele of alpha 1-antitrypsin, and p-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 1996, 11:438-443.
36. Sugimori T, Cooley J, Hoidal JR, Remold-O'Donnell E: Inhibitory properties of recombinant human monocyte/neutrophil elastase inhibitor. Am J Respir Cell Mol Biol 1995, 13:314-322.
37. Evans E, Cooley J, Remold-O'Donnell E: Characterization and chromosomal localization of ELANH2, the gene encoding human monocyte/neutrophil elastase inhibitor. Genomics 1995, 28:235-240.
38. Zimmer M, Medcalf RL, Fink TM, Mattmann C, Lichter P, Jenne DE: Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19 pter. Proc Natl Acad Sci U S A 1992, 89:8215-8219.
39. Schwaller J, Chen T, Fey MF, Tobler A: A myeloblastln/proteinase-3 cDNA clone identifies a Bgl II and a Pvu II restriction length polymorphism. Hum Genet 1993, 92:525.
40. Jenne DE: Gene structure of ANCA target antigens: implications for • the pathogenesis of vasculitis. Sarcoidosis Vasculitis and Diffuse Lung Diseases 1996, 13:209-213. A concise review of the genetic background of SV, focusing on ANCA target antigens and their genetic polymorphisms.
41. Jenne DE: Structure of the azurocidin, proteinase 3, and neutrophil elastase genes. Implications for inflammation and vasculitis. Am J Respir Crit Care Med 1994, 150:S147-S154.
42. Tse WY, Quibell K, Kumararatne DS, Jefferis R, Bacon P, Savage COS, Adu D: Neutrophil Fc γRIIa-receptor polymorphisms in ANCA-positive vasculitis [abstract]. Sarcoidosis Vasculitis and Diffuse Lung Diseases 1996, 13(3):269.
43. Brouwer E, Cohen Tervaert JW, Horst G, Huitema MG, van der Giessen M, Limburg PC, Kallenberg CGM: Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wagener's granulomatosis and clinically related disorders. Clin Exp Immunol 1991, 83:379-386.
44. Taniguchi Y, Ito MR, Mori S, Yonehara S, Nose M: Role of macrophages •• in the development of arteritis in MRL strains of mice with a deficit in Fas-mediated apoptosis. Clin Exp Immunol 1996, 106:26-34. A study showing that both MRL/lpr and MRL/gld mice strains can develop spontaneously granulomatous arterilis, with infiltration by Mac-2 macrophages and CD4-T cells, due to defective apoptolic mechanisms. M-CSF was shown to enhance Fas antigen and Mac-2 expression on spleen cells from MRL/+ mice, as well as granuloma formation. It suggests that apoptotic defective mechanisms can be important in the development of vascular inflammation.
45. Rollino C, Roccatello D, Borsa S, Bellone G, Piccoli G, Emanuelli G: Antibodies directed to sonicated human endothelial cells in patients with vasculitis. Nephron 1996, 73:346-347.
46. Eichhorn J, Sima D, Thiele, Lindschau C, Turowski A, Schmidt H, Schneider W, Haller H, Luft FC: Anti-endothelial cell antibodies in Takayasu arterltis. Circulation 1996, 94:2396-2401.
47. Savage COS, Cooke SP: The role of endothelium in systemic vasculitis. J Autoimmun 1993, 6:237-249.
48. Bratt J, Palmblad J: Cytokine-induced neutrophil-mediated injury of •• human endothelial cells. J Immunol 1997, 159:912-918. A study showing how different cytokines activate human umbilical vein endothelial cells and render them sensitive to polymorphonuclear nitric oxide toxicity. It also analyzes the role of nitric oxide in mediating cytotoxicity.
49. Pall AA, Savage COS: Mechanisms of endothelial cell injury in vasculitis. Springer Semin Immunopathol 1994, 16:23-37.
50. Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P: Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol 1992, 140:301-316.
51. Berger SP, Seelen HAJ, Hiemstra PS, Gerritsma JSJ, Heemskerk E, van • der Woude FJ, Daha MR: Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro. J Am Soc Nephrol 1996, 7:694-701. By using a sandwich ELISA technique and Northern blot analysis, the authors show that Pr-3 and elastase increase interleukin-8 de novo synthesis by endothelial cells.
52. Savage COS, Harper L, Adu D: Primary systemic vasculitis. Lancet • 1997, 349:553-558. A concise, complete review covering fundamental aspects of SV.
53. Boehme MWJ, Schmitt WH, Youinou P, Stremmel WR, Gross WL: Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wagener's granulomatosis and other systemic vasculitides. Am J Med 1996, 101:387-394.
54. Van der Woude FJ, Rasmussen N, Lobatto S, et al.: Autoantibodies to neutrophils and monocytes: a new tool for diagnosis and a marker of disease activity in Wegener's granulomatosis. Lancet 1985, ii:425-429.
55. Haller H, Eichhorn J, Pieper K, Göbel U, Luft FC: Circulating leukocyte integrin expression in wegener's granulomatosis. J Am Soc Nephrol 1996, 7:40-48.
56. Forde AM, Feighery C, Jackson J: Anti-monocyte cytoplasmic antibodies in granulomatous disease. Clin Immunol Immunopathol 1996, 81:88-95.
57. Dang-Vu AD, Pisetsky DS, Weinberg JB: Functional alterations of macrophages in autoimmune MRL-lpr/lpr mice. J Immunol 1987, 138:1757-1761.
58. Sahin S, Lawrence R, Direskeneli H, Hamuryudan V, Yazici H, Akoglu T: Monocyte activity in Behcet's disease. Br J Rheumatol 1996, 35:424-429.
59. Salvarani C, Macchioni P, Borardi L: Polymyalgia rheumatica. Lancet 1997, 350:43-49.
60. Falk RJ, Terrell RS, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990, 87:4115-4119.
61. Qasim FJ, Mathieson PW, Sendo F, Thiru S, Oliveira DBG: Role of •• neutrophils in the pathogenesis of experimental vasculitis. Am J Pathol 1996, 149:81-89. A study using a rat model of vasculitis and showing that a monoclonal antibody bound to polymorphonuclear reduced the neutrophil infiltration of the gut vascular wall, preventing subsequent injury.
62. Grimminger F, Mattar K, Papavassilis C, Temmesfeld B, Csernok E, Gross WL, Seeger W, Sibelius U: Neutrophil activation of anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotrlene B4 generation. J Exp Med 1996, 184:1567-1572.
63. Heeringa P, van Goor H, Moshage H, Klok PA, Huitema MG, de Jager A, •• Schep AJ, Kallenberg CGM: Expression of iNOS, eNOS and peroxynitrite-modified proteins in experimental anti-myeloperoxidase associated crescentic glomerulonephritis. Kidney Int, accepted for publication. A study of an animal model of necrotizing crescentic glomerulonephritis, showing decreased eNOS and increased iNOS expression of glomeruli and interstitium on rats immunized with MPO and having later perfused their kidneys with a lysosomal polymorphonuclear extract and hydrogen peroxide, in comparison with absence of similar changes in a control group.
64. Mayet WJ, Schwarting A, Orth T, Duchmann R, Meyer zum Büschenfelde KH: Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1). Clin Exp Immunol 1996, 103:259-267.
65. Noronha IL, Krüger C, Andrassy K, Ritz E, Waldherr R: In situ production of TNF-α, IL1β and IL2R in ANCA-positive glomerulonephritis. Kidney Int 1993, 43:682-692.
66. Brooks CS, King WJ, Radford DS, Adu D, McGrath M, Savage COS: IL1β-production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic auto-antibodies: relevance to systemic vasculitis. Clin Exp Immunol 1996, 106:273-279.
67. Csernok E, Symkowiak CH, Mistry N, Daha MR, Gross WL, Kekow J: • Transforming growth factor-beta (TGF-β) expression and interaction with proteinase-3 (Pr3) in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Clin Exp Immunol 1996, 105:104-111. A study using different techniques and showing increased transforming growth factor-β expression in patients with Wegener's granulomatosis, Churg-Strauss syndrome and MPA, and also used on a group of patients with vasculitis secondary to rheumatoid arthritis. Transforming growth factor-β also induced translocation of Pr-3 to the polymorphonuclear membrane.
68. Niwa Y, Ozaki Y, Kanoh T, Akamatsu H, Kurisaka M: Role of cytokines, tyrosine kinase, and protein kinase C on production of Superoxide and induction of scavenging enzymes in human leukocytes. Clin Immunol Immunopathol 1996, 79:303-313.
69. Hagen EC, Andrassy K, Csemok E, Daha MR, Gaskin G, Gross WL, Hansen B, Heigl Z, Hermans J, Jayne D, Kallanberg CGM, Lesavre PH, Lockwood CM, Lüdemann J, Mascart-Lemone F, Mirapeix E, Pusey CD, Rasmussen N, Sinico RA, Tzioufas A, Wieslander J, Wiik A, van der Woude FJ: Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report of the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 1996, 196:1-15.
70. Specks U, Fass DN, Fautsch MP, Hummel AM, Viss M: Recombinant • human proteinase 3, the Wegener's autoantigen, expressed in HMC-1 cells is enzymatically active and recognized by c-ANCA. FEBS Lett 1996, 390:265-270. The first successful expression of recombinant Pr-3 that is enzymatically active and recognized by ANCA.
71. Sobajima J, Ozaki S, Okazaki T, Osakada F, Sumita S, Mori K, Nakao K: Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type. Clin Exp Immunol 1996, 105:120-124.
72. Yang JJ, Tuttle R, Falk RJ, Jennette JC: Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease. Clin Exp Immunol 1996, 105:125-131.
73. Zhao MH, Lockwood CM: Azurocidin is a novel antigen for antineutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Clin Exp Immunol 1996, 103:397-402.
74. Peen E, Almer S, Bodemar G, Ryden BO, Sjölin C, Tejle K, Wskogh T: Anti-lactoferrin antibodies and other types of ANCA in Crohn's disease, ulcerative colitis, and primary sclerosing cholangitis. Gut 1993, 34:56-62.
75. Mulder AHL, Horst G, van Leeuwen MA, Umburg PC, Kallenberg CGM: Anti-neutorphil cytoplasmic antibodies in rheumatoid arthritis. Arthritis Rheum 1993, 36:1054-1060.
76. Kain R, Matsui K, Exner M, Binder S, Schaffner G, Sommer EM, Kerjaschki D: A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothellal cells. J Exp Med 1995, 181:585-597.
77. Kannan K, Stewart RM, Bounds W, Carlsson SR, Fukuda M, Betzing KW, Holcombe RF: Lysosome-assoclated membrane proteins h-lamp-1 (CD107a) and h-lamp-2 (CD107b) are activation-dependent cell surface glycoproteins in human peripheral blood mononuclear cells which mediate cell adhesion to vascular endothellum. Cell Immunol 1996, 171:10-19.
78. Gilligan HM, Bredy B, Brady HR, Hebert MJ, Slayter HS, Xu Y, Rauch J, Shia MA, Koh JS, Levine JS: Antineutrophil cytoplasmlc autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 1996, 184:2231-2241.
79. Keogan MT, Rifkin I, Ronda N, Lockwood CM, Brown DL: Antineutrophil cytoplasm antibodies increase neutrophil adhesion to cultured human endothelium. Adv Exp Med Biol 1993, 336:115-119.
80. Ralston DR, Marsh CB, Lowe MP, Wewers MD: Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, α1-antitrypsin, and fcγ receptors. J Clin Invest 1997, 100(6):1416-1424.
81. Kettritz R, Jennette JC, Falk RJ: Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol 1997, 8:388-394.
82. Mulder AH, Heeringe P, Brouwer E, Limburg PC, Kallenberg CG: Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol 1994, 98:270-278.
83. Porges AJ, Redecha PB, Taylor Kimberly W, Csemok E, Gross WL, Kimberly RP: Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophlis via FcγRIIa. J Immunol 1994, 153:1271-1280.
84. Mayet WJ, Csemok E, Szymkowiak C, Gross WL, Meyer zum Büschenfelde KH: Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood 1993, 82:1221-1229.
85. Schwarting A, Schlaak JF, Wandel E, Meyer zum Büschenfelde K-H, Mayet WJ: Human renal tubular epithelial cells as target cells for antibodies to proteinase 3 (c-ANCA). Nephrol Dial Transplant 1997, 12:916-923.
86. King WJ, Adu D, Daha MR, et al.: Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3. Clin Exp Immunol 1995, 102:98-105.
87. Yang JJ, Kettritz R, Falk RJ, Jennette JC, Gaido ML: Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. Am J Pathol 1996, 149:1617-1626.
88. Heeringa P, van den Born J, Brouwer E, Dolman KM, Klok PA, Huitema MG, Limburg PC, Bakker MAH, Berden JHM, Daha MR, Kallenberg CGM: Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo renal perfusion in rats. Clin Exp Immunol 1996, 105:321-329.
89. Brouwer E, Huitema MG, Klok PA, de Weerd H, Cohen Tervaert JW, Weening JJ, Kallenberg CGM: Anti-myeloperoxidase associated proliferative glomerulonephritis: an animal modal. J Exp Med 1993, 177:905-914.
90. Dolman KM, Stegeman CA, van de Wiel BA, Hack CE, von dem Borne AEGKr, Kallenberg CGM, Goldschmeding R: Relevance of c-ANCA mediated inhibition of proteinase 3-alpha 1-antitrypsin complexation to disease activity in Wegener's granulomatosis. Clin Exp Immunol 1993, 93(3):405-410.
91. Wiel BA van de, Dolman KM, Meer-Gerritsen CH van der, Hack CE: Interference of Wegener's Granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 1992, 90:409-414.
92. Segelmark M, Persson B, Hellmark T, Wieslander J: Inhibition of myeloperoxidase by ceruloplasmin (abstract). Sarcoidosis, Vasculitis and Diffuse Lung Disease 1996, 13:264.
93. Daouk GH, Palsson R, Arnaout MA: Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis. Kidney Int 1995, 47:1528-1536.